PREVENTKD (Prevent Risks by Early interVEntion at Nighttime in Type 1 Diabetes for Kidney Disease)

Type 1 Diabetes Clinical Trial

— PREVENTKD  

Official title:

Nocturnal Hypertension and Prevention of Microalbuminuria in Type 1 Diabetes

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00729365
• Other study ID #: 1U01DK071733-01A1
• Secondary ID: 1U01DK071733-01A
• Status: Terminated
• Phase: Phase 3
• First received: August 4, 2008
• Last updated: February 24, 2015
• Start date: July 2008
• Est. completion date: June 2010

Study information

• Verified date: February 2015
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if the early treatment with a blood pressure medication (an ACE Inhibitor) can prevent or delay the development of kidney disease (microalbuminuria) in patients with Type 1 diabetes who have normal blood pressure and urine albumin levels.

Description:

Only a fraction of persons with Type 1 diabetes (less than 40%) develop diabetic kidney disease (nephropathy). When the urinary albumin (a protein normally excreted in small amounts) is within the normal range, the prevalence of high blood pressure (hypertension) based on office blood pressure readings is very low. Many of these persons, however, develop nocturnal hypertension (high nighttime blood pressure) before the development of abnormally high urinary albumin excretion (a condition referred to as microalbuminuria). Currently, early treatment with medications called ACE inhibitors is only recommended after there is an indication of kidney damage, as reflected by the presence of microalbuminuria. Beginning ACE inhibitor therapy is currently not recommended prior to the development of microalbuminuria, unless patients have high blood pressure, because it would result in over-treatment of many people. By the time that microalbuminuria develops, however, kidney damage may be present and many patients will develop kidney disease. It would therefore be beneficial to identify those subjects who will develop microalbuminuria, so that treatment could be started early for those individuals. Persons who may go on to develop protein in their urine and eventual kidney disease perhaps could be identified on the basis of an abnormal fall (too little) in blood pressure at night. This pattern should not be confused with high blood pressure, but instead seen as an early indication present before the development of high blood pressure and microalbuminuria.

The purpose of the current study is therefore aimed at demonstrating that it is possible to prevent kidney disease in patients with type 1 diabetes and normal office blood pressure and urine protein excretion by selecting them on the basis of an abnormal fall in blood pressure at night. Moreover, this clinical trial will reveal the impact of long-term administration of an ACE inhibitor on nighttime blood pressure and also assess changes in the relative stiffness of blood vessels(endothelial dysfunction) in persons with type 1 diabetes over time.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 65
• Est. completion date: June 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 13 Years to 50 Years

Eligibility

Inclusion Criteria:

• Subjects with type 1 diabetes confirmed by C peptide measurements.

• Male and Female subjects of all races will be included in this study.

• Subjects age must be between 13 to 50 years

• Duration of the disease (from time of diagnosis of diabetes) must be between 5 to 28 years.

• Subjects must be normotensive defined as a systolic blood pressure of = 130 mmHg and diastolic of = 85 mmHg in subjects 18 and older and for children (ages 13-17) blood pressure will be in the normal range based on standard tables which takes in to account gender, height and age.

• The mean 24 blood pressure must meet the same criteria as the office blood pressures outlined above.

• Subject must have normoalbuminuria (UAE < 30 mg/24 hrs)

• If subject is a female she must not be breast-feeding, and not of child-bearing potential, defined as post-menopausal for at least 1 year or surgically sterile; if she is of child bearing potential, then she must be practicing one of the following methods of birth control: 1) condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), 2) contraceptives (oral or parenteral) initiated three months prior to study drug administration, 3) maintain a monogamous relationship with a vasectomized partner, or 4) total abstinence from sexual intercourse.

Exclusion Criteria:

• Type 2 diabetics and other types of diabetics such as those with maturity onset diabetes or the young (MODY) will be excluded on the basis of established clinical criteria.

• Subjects who have a history of hypertension or is taking any hypertensive medications.

• Females who are pregnant or express a desire to become pregnant during the study. Females who are breast-feeding. Refer to details in inclusion criteria above regarding females.

• Subjects who have a history of taking ACE inhibitors within the last six months or have a current indication for ACE inhibitor therapy.

• Subjects (18 years of age and over) with a current blood pressure above 130mmHg/85mmHg. Subjects (13-17 years of age) who do not meet the normal range based on the standard tables

• Subjects who are currently microalbuminuric i.e. 24hr albumin > 30mg

• Subjects who have participated in an interventional clinical trial involving ABPM 6 months prior to this study.

• Subjects that have a diagnosis of chronic atrial fibrillation.

• Subjects with a lifestyle that would disrupt normal circadian rhythm (i.e. night-shift workers).

• Subjects with a current serious co-morbid condition for which life expectancy is <2 years.

• Subjects with a history of non-compliance, or psychiatric disturbance that would preclude successful completion of the study.

• Inability to give informed consent.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Drug:
• Ramipril
ACE inhibitor known as Ramipril Subjects with nighttime blood pressure that does not drop during the night ("non-dippers") maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the "Non-Dippers" groups II and III will be randomized to receive either drug or placebo.
• Placebo
Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
• Placebo
Subjects with nighttime blood pressure that does not drop during the night ("non-dippers") maybe randomized into the control group and given Placebo.

Locations

Country	Name	City	State
United States	Northwestern University Feinberg School of Medicine	Chicago	Illinois
United States	Rush University Medical Center, Endocrinology Section	Chicago	Illinois
United States	University of Chicago	Chicago	Illinois
United States	University of Illinois at Chicago	Chicago	Illinois
United States	University of Florida	Gainesville	Florida
United States	Loyola University Chicago	Maywood	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
Northwestern University	Juvenile Diabetes Research Foundation, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005 Jul;46(1):156-61. Epub 2005 Jun 6. — View Citation

Haller MJ, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing MG, Lerman A, Mahmud FH. Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatr Diabetes. 2007 Aug;8(4):193-8. — View Citation

Lurbe A, Redón J, Pascual JM, Tacons J, Alvarez V, Batlle DC. Altered blood pressure during sleep in normotensive subjects with type I diabetes. Hypertension. 1993 Feb;21(2):227-35. — View Citation

Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, Batlle D. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002 Sep 12;347(11):797-805. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Development of Microalbuminuria (High Urine Albumin). Hypertension, Urine and Blood Markers Will Also be Evaluated for Assessment of Kidney Disease State.		at 3months and then every 6months during the 5years of the study	Yes
Secondary	We Will Assess Changes in the Relative Stiffness of Your Arteries (Endothelial Dysfunction) in Persons With Type 1 Diabetes Over the 5year Study.		year 1, 3, 5 and after the washout phase (5years and 1month)	No